miR-615, AKT/eNOS signaling, and angiogenesis

miR-615、AKT/eNOS 信号传导和血管生成

• 批准号: 9973357
• 负责人: MARK W FEINBERG
• 金额: $ 68.56万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-15 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9973357
• 关键词: 3' Untranslated Regions; AKT inhibition; Acute; Base Pairing; Binding; Biological Assay; Biology; Blood Vessels; Blood capillaries; Blood flow; Brain; Cardiovascular Diseases; Cardiovascular Physiology; Cardiovascular system; Cell Proliferation; Cell physiology; Cellular biology; Chronic; Clinical Research; Deletion Mutation; Disease; Endothelial Cells; Endothelium; FGF2 gene; Foundations; Gene Expression; Genes; Genetic Transcription; Goals; Growth; Growth Factor; Health Expenditures; Heart; Hindlimb; Human; IGF2 gene; Impairment; Infarction; Injections; Ischemia; Knockout Mice; Leg; Ligation; Limb structure; Link; Mediating; Mediator of activation protein; Messenger RNA; MicroRNAs; Molecular; Morbidity - disease rate; Mus; Myocardial; Myocardial Infarction; Myocardial Ischemia; Nitric Oxide; Organoids; Outcome; Participant; Pathway interactions; Patients; Peripheral arterial disease; Phenocopy; Plasma; Process; Proliferating; Proto-Oncogene Proteins c-akt; Publishing; Recovery; Regulation; Reperfusion Therapy; Reporter Genes; Resistance; Role; Signal Pathway; Signal Transduction; Stimulus; Therapeutic; Thrombospondin 1; Tissue Sample; Tissues; Tube; United States; Untranslated RNA; Untranslated Regions; Vascular Endothelial Cell; Vascular Endothelial Growth Factors; acute coronary syndrome; angiogenesis; artery occlusion; blood vessel development; cell growth; cell motility; crosslinking and immunoprecipitation sequencing; human disease; human subject; human tissue; improved; in vivo; inhibitor/antagonist; insight; intravenous administration; ischemic injury; loss of function; matrigel; migration; molecular imaging; mortality; myocardial infarct sizing; nanoparticle; neovascularization; novel; novel therapeutic intervention; novel therapeutics; overexpression; perfusion imaging; preclinical study; response; response to injury; tissue repair; transcriptome sequencing; transcriptomics; wound closure

Ischemic cardiovascular disease (CVD) due to atherosclerotic occlusion of the arteries to the heart, legs, or brain is associated with considerable morbidity, mortality, and health care expenditure in the United States. The induction and orchestration of new blood vessels is critical for tissue repair in response to injury such as myocardial infarction or peripheral artery disease (PAD). In response to pro-angiogenic stimuli, vascular endothelial cells (ECs) are activated to migrate and proliferate to form primary capillaries. However, despite the importance of ECs in neoangiogenesis, our understanding of the mechanisms regulating this process remains poorly understood. Emerging studies indicate that the inability of angiogenic growth factors to stimulate angiogenesis is likely due to impaired angiogenic signaling and not due to deficiency in these growth factors. MicroRNAs (miRNAs) are small, single-stranded, non-coding RNAs capable of repressing gene expression by base pairing to the 3' untranslated regions (3'-UTRs) of mRNA targets and are involved in a variety of pathophysiological processes in cardiovascular biology, though their function in angiogenesis and angiogenic signaling pathways remains poorly defined. We undertook a microarray profiling approach of plasma from subjects with ischemic CVD and identified that miR-615-5p expression is increased by ischemia and reduced in response to pro-angiogenic stimuli–observations that are recapitulated in both mice and human ischemic paradigms in vivo. Preliminary and published gain and loss-of-function studies reveal that miR-615-5p overexpression markedly impaired EC proliferation, migration, and network tube formation in matrigel, whereas blockade of miR-615-5p had the opposite effects. Mechanistically, using unbiased transcriptomic profiling, we find that miR-615-5p suppressed EC proliferation and binding to 2 unique targets–RASSF2 and IGF2–in their 3'-UTRs and reduced their expression, an effect that selectively regulated the AKT/eNOS signaling pathway in ECs. Finally, systemic intravenous administration of miR-615-5p inhibitors increased blood vessel formation and reduced infarct size and improved blood flow recovery in ischemic legs compared to mice that received scrambled control anti-miR injections. These observations provide the foundation for the central hypothesis that miR-615-5p may serve as a critical regulator of EC proliferation and angiogenic responses. To better understand the precise role of miR-615-5p in AKT/eNOS signaling and angiogenesis, we will in Aim1 delineate the upstream mechanisms governing miR-615-5p expression in ECs. In Aim2, we will determine the molecular basis for miR-615-5p's ability to regulate AKT/eNOS signaling and EC functions critical to angiogenesis. In Aim3, we will explore the effect of altering miR-615-5p expression in the microvasculature on acute and chronic experimental ischemic injury. The results of these studies will provide insights regarding miR-615-5p function in EC biology, pathophysiological angiogenesis, and cardiovascular ischemic states and may provide new targets to rescue impaired angiogenic signaling for a range of ischemic cardiovascular disease states.

缺血性心血管疾病（CVD），由于动脉粥样硬化闭塞的动脉到心脏，腿，或